Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047010 | 0.85 | ALDH1A1 (0.61) | ALDH1A1HPGDSMN1; SMN2TP53NFKB1 | |
| SCHEMBL5025952 | 0.84 | ALDH1A1 (0.48) | ALDH1A1HPGDSMN1; SMN2TP53NFKB1 | |
| SCHEMBL1049550 | 0.84 | TARBP2 (0.53) | ALDH1A1HPGDSMN1; SMN2TP53HSD17B10 | |
| SCHEMBL1435871 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2TP53NFKB1 | |
| SCHEMBL27621046 | 0.80 | NOTUM (0.42) | ALDH1A1HPGDSMN1; SMN2TP53KDM4E | |
| SCHEMBL3294077 | 0.78 | POLB (0.55) | ALDH1A1HPGDHSD17B10KDM4EMAPT | |
| Anisaldehyde SCHEMBL4253513 | 0.76 | LMNA (0.50) | ALDH1A1HPGDSMN1; SMN2TP53HSD17B10 | |
| SCHEMBL1051303 | 0.74 | ALDH1A1 (0.51) | ALDH1A1HPGDSMN1; SMN2TP53HSD17B10 | |
| SCHEMBL1047012 | 0.73 | KDM4E (0.64) | HPGDTP53KDM4EPPARGPPARD | |
| SCHEMBL1048006 | 0.73 | TP53 (0.49) | ALDH1A1HPGDSMN1; SMN2TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599453-B1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-7365084-B2 | Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-29 | — | — | US | disclosed |
| EP-1599453-A1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050215596-A1 | Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-29 | — | — | US | disclosed |
| WO-2004076426-A1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215596-A1 | Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals | DNPEP, DDC, AADAT | ALDH1A1 3240/4885HPGD 2813/4885SMN1; SMN2 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.